475 studies found for:    "Fallopian tube cancer"
Show Display Options
Rank Status Study
21 Completed Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: pegfilgrastim;   Drug: carboplatin;   Drug: docetaxel;   Drug: erlotinib hydrochloride
22 Terminated Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction
Conditions: Ovarian Cancer;   Peritoneal Cancer;   Fallopian Tube Cancer;   Bowel Obstruction
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
23 Terminated Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Neoplasms
Intervention:
24 Active, not recruiting TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions: Drug: AMG 386;   Drug: AMG 386 Placebo;   Drug: Paclitaxel
25 Not yet recruiting Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Carboplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
26 Active, not recruiting Autologous T Cells With or Without Cyclophosphamide and Fludarabine in Treating Patients With Recurrent or Persistent Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer (Fludarabine Treatment Closed as of 12/01/2009)
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis
27 Active, not recruiting PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer
Conditions: Epithelial Ovarian Cancer;   Primary Peritoneal Carcinoma;   Primary Fallopian Tube Cancer
Interventions: Drug: IMGN853;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Gemcitabine;   Drug: Topotecan
28 Active, not recruiting Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Conditions: Anxiety;   Fatigue;   Nausea and Vomiting;   Neurotoxicity Syndrome;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage I Ovarian Cancer;   Stage IA Fallopian Tube Cancer;   Stage IB Fallopian Tube Cancer;   Stage IC Fallopian Tube Cancer;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIC Fallopian Tube Cancer;   Stage III Ovarian Cancer;   Stage III Primary Peritoneal Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Procedure: Assessment of Therapy Complications;   Other: Medical Chart Review;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
29 Active, not recruiting OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission
Conditions: Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Polyvalent Antigen-KLH Conjugate Vaccine;   Biological: Saponin-based Immunoadjuvant OBI-821
30 Active, not recruiting Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Breast Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Breast Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Biological: Multi-epitope Folate Receptor Alpha Peptide Vaccine
31 Active, not recruiting Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Conditions: Malignant Ovarian Mixed Epithelial Tumor;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Biological: Bevacizumab;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment
32 Terminated Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Drug: gemcitabine hydrochloride;   Drug: topotecan hydrochloride
33 Withdrawn Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Drug: carboplatin;   Drug: gemcitabine hydrochloride
34 Completed Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Neuropathy;   Neurotoxicity Syndrome;   Pain;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Carboplatin;   Drug: Glutathione;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
35 Completed
Has Results
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
Conditions: Ovarian Cancer;   Peritoneal Primary Cancer;   Fallopian Tube Cancer
Interventions: Other: healing touch;   Other: massage therapy;   Other: hypnosis;   Drug: Standard chemotherapy
36 Completed
Has Results
AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Cancer;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Epithelial Cancer;   Stage I Ovarian Epithelial Cancer;   Stage II Ovarian Epithelial Cancer
Intervention: Drug: cediranib maleate
37 Recruiting Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention: Drug: regorafenib
38 Completed Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Interventions: Drug: RAD001;   Drug: bevacizumab
39 Terminated
Has Results
Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Serous Cancer;   Fallopian Tube Cancer
Intervention: Drug: bevacizumab
40 Not yet recruiting A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Neoadjuvant Treatment;   Debulking Surgical Procedures
Interventions: Drug: Olaparib;   Drug: Platinum-based Chemotherapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years